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   DETERMINATION OF HUMAN GROWTH 
HORMONE IN PURE AND PHARMACEUTICAL 
DOSAGE FORM BY SPECTROFLUOROMETRY
AND HIGH PERFORMANCE LIQUID 
CHROMATOGRAPHY 
In this study, new and rapid spectrofluorometry and high performance liquid 
chromatography (HPLC) methods were developed for determination of human 
growth hormone in pure and pharmaceutical dosage form. The solvent system, 
wavelength of detection and chromatographic conditions were optimized in 
order to maximize the sensitivity of both the proposed methods. Linearity was 
established over the concentration range of 1.25-50 μg mL
-1 for spectrofluoro-
metry and 10-75 μg mL
-1 for HPLC method. The intra- and inter-day relative 
standard deviation (RSD) was less than 8.46 and 5.98% for spectrofluorometry 
and HPLC, respectively. Limits of quantitation were determined as 0.075 and 
7.5 μg mL
-1 for spectrofluorometry and HPLC, respectively. No interference 
was found from tablet excipients at the selected assay conditions. The me-
thods were applied for the quality control of commercial growth hormone do-
sage form to quantify the drug and to check the formulation content uniformity. 
Keywords: growth hormone; spectrofluorometry; HPLC; validation. 
 
 
Synthetic human growth hormone is manufac-
tured by recombinant DNA technology. It is a 191 amino 
acid polypeptide (MW 22 kDa) with an amino acid se-
quence and two internal disulphide bridges identical 
to that of the major component of human pituitary 
growth hormone. Therapeutically, growth hormone is 
used in children to treat growth retardation, for ex-
ample short stature due to insufficient growth hor-
mone secretion, Turner’s syndrome or chronic renal 
insufficiency. In adults it is used as a treatment for 
growth hormone deficiency and for management of 
HIV-related wasting and cachexia [1].  
Several analytical methods for the qualitative 
and quantitative determination of growth hormone have 
been described, such as sodium dodecyl sulfate-poly-
acrylamide gel electrophoresis (SDS-PAGE) frequen-
tly combined with immunoblotting [2-4], capillary zone 
electrophoresis [5], size-exclusion [6], hydrophobic-
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interaction [7,8], reversed-phase high-performance li-
quid chromatography (HPLC) [9,10], liquid chromate-
graphy-mass spectrometry (LC-MS) [11] and enzyme-
linked immunosorbent assay (ELISA) [12,13]. The 
pharmacokinetics and the quantitation of growth hor-
mone has been described in sheep [1], rabbit [13] hu-
man plasma [14] and dog serum [15] by chemilumi-
nescent immunometric assay, ELISA, radioimmuno-
assay, immunoradiometric assay, respectively. 
An extensive survey of literature revealed no 
spectrofluorometry method reported to date for deter-
mination of growth hormone in pure and pharmaceu-
tical dosage forms. However, literature survey re-
vealed HPLC methods for determination of growth 
hormone. An HPLC method for growth hormone using 
TSKG3000SW column and mobile phase of sodium 
borate (pH 7.3)-EDTA has been reported [6]. Another 
study is a reverse phase HPLC method [10], which 
utilized phosphate-buffered saline (0.12 M NaCl, 0.025 
M phosphate, pH 7.0) as a mobile phase system for 
growth hormone. Over the last 10 years, HPLC me-
thods using UV detection technique have been re-
ported for the determination of growth hormone [6-10]. B. YILMAZ et al.: DETERMINATION OF HUMAN GROWTH HORMONE…  CI&CEQ 18 (3) 399−405 (2012) 
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This paper describes a spectrofluorometry me-
thod for determination of growth hormone and an 
HPLC method using a reverse phase C18 column in 
the mixture of water mobile phase consisting of 0.1% 
H3PO4 with UV detection. The spectrofluorometry me-
thod was aimed at developing an easy and rapid as-
say method for growth hormone without any time con-
suming sample preparation steps for routine analysis 
[16]. The HPLC method attempted to demonstrate the 
utility of UV detection for determination of growth hor-
mone coupled with simple and economical mobile 
phase and reasonable analysis time with high preci-
sion.  
In both the proposed methods, there is no need 
to extract the drug from the formulation excipient mat-
rix thereby decreasing the error in quantization. For-
mulation samples can be directly used after dissolving 
and filtration. The developed methods were used to 
determine the total drug content in commercially 
available pharmaceutical preparation of growth hor-
mone. 
EXPERIMENTAL 
Chemicals 
Human growth hormone was obtained from Eli 
Lilly and Company (Indianapolis, USA). Humatrope 
was a gift from Eli Lilly (Istanbul, Turkey). All che-
micals were of analytical grade. Buffer solution (po-
tassium dihydrogen phosphate, KH2PO4) was pre-
pared with deionized water by using an aquaMAX™ 
ultra, Young instrument (Korea) ultrawater purification 
system.  
Spectrofluorometric and chromatographic system  
All fluorescence measurements were done on a 
Shimadsu RF-5301 PC spectrofluorometer equipped 
with a 150 W Xenon lamp. Experimental parameters 
were slit width 5.0 nm, λexc = 275 nm and λem = 335 nm. 
The HPLC system consisted of a Thermosepa-
rations Spectra Series P 4000 gradient pump coupled 
with a Spectra System UV 6000 detection and a Ther-
moseparations AS 3000 auto sampler, a SCM 1000 
vacuum membrane degasser, a SN 4000 system con-
troller. The detector was set at 220 nm, which was the 
wavelength used for quantification. Separation was 
operated on a Luna reversed-phase C18 column with 
particle size of 5 μm (250 mm×4.6 mm i.d.) using a 
water mobile phase consisting of 0.1% H3PO4 at a 
flow rate of 0.5 ml min
-1. The UV detector was ope-
rated at 220 nm and column temperature was ad-
justed at 55 °C. 50 μL of samples was injected to the 
HPLC system. 
Preparation of the standard and quality control 
solutions 
The stock solution of growth hormone was pre-
pared in 25 mM phosphate buffer solution to a con-
centration of 650 μg mL
-1. Phosphate buffer was pre-
pared in double distilled filtered water and its pH was 
adjusted to 7.4±0.02 with sodium hydroxide solution. 
Standard solutions were prepared as 1.25-50 μg mL
-1 
(1.25, 2.5, 5, 10, 20, 30, 40 and 50 μg mL
-1) for 
spectrofluorometry and 10-75 μg mL
-1 (10, 20, 30, 40, 
50 and 75 μg mL
-1) for the HPLC method.  
The quality control (QC) samples were prepared 
by adding aliquots of standard working solution of 
growth hormone to final concentrations of 2, 12.5 and 
35 μg mL
-1 for the spectrofluorometry and 15, 35 and 
60 μg mL
-1 for the HPLC method.  
Procedure for pharmaceutical preparation 
Humatrope injectable form containing growth 
hormone (1.33 mg) was accurately weighed and 
transferred into 10 mL volumetric flask and 2 mL 25 
mM phosphate buffer solution was added. Further di-
lutions were performed to suit the calibration graphs 
for the spectrofluorometry and HPLC methods (15 
and 50 μg mL
-1).  
Data analysis 
All statistical calculations were performed with 
the Statistical Product and Service Solutions (SPSS) 
for Windows, version 10.0. Correlations were con-
sidered statistically significant if calculated P values 
were 0.05 or less. 
RESULTS AND DISCUSSION 
Method development and optimization 
For spectrofluorometry method, various solvent 
systems (water, methanol and phosphate buffer) were 
investigated. The final decision for using phosphate 
buffer as the solvent was based on sensitivity, suit-
ability for drug content determination and stability stu-
dies. 
In the case of HPLC, method development was 
focused on the optimization of column detection, sample 
preparation and chromatographic separation. A re-
versed-phase column (C18) can be used for the sepa-
ration of non-ionic as well as ion forming non-polar to 
medium polar substances while normal phase chro-
matography can be used for the separation of non-
ionic and/or non-polar substances. Majority of the io-
nizable pharmaceutical compounds can be very well 
separated on a C18 column [17]. Thus, growth hor-
mone can be satisfactorily separated by reversed phase 
chromatography. B. YILMAZ et al.: DETERMINATION OF HUMAN GROWTH HORMONE…  CI&CEQ 18 (3) 399−405 (2012) 
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Several tests were performed for optimizing the 
components of mobile phase in order to achieve good 
chromatographic peak shape and resolution. The test 
results showed that the solvent system of water could 
improve the peak shapes of growth hormone. Good 
separation of target compound and short run time 
were obtained using a mobile phase system of water 
consisting of 0.1% H3PO4. The retention time of growth 
hormone (4.7 min) was quite shorter than that studied 
by Chang et al. [6] and Oliva et al. [10]. On the other 
hand, the mobile phase in the proposed method is 
water consisting of 0.1% H3PO4  instead of buffered 
systems, as used in previously reported HPLC me-
thods [6,10]. 
Validation of the methods 
To evaluate the validation of the present me-
thods, parameters as specificity, linearity, precision, 
accuracy, limit of detection (LOD), limit of quantitation 
(LOQ), recovery and stability were investigated ac-
cording to ICH validation guidelines [18].  
Selectivity 
All the solutions were scanned from 250 to 450 
nm at a slit width of 5.0 nm and checked for change in 
the emission at respective wavelengths (Figure 1). 
In a separate study, the selectivity of the HPLC 
method was investigated by observing interferences 
between growth hormone and excipients. The reten-
tion time of growth hormone in HPLC method was 
approximately 4.7 min with good peak shape (Figure 2). 
A study of some potential interfering substances 
in the HPLC determination of growth hormone was 
performed by selecting them as the excipients often 
used in pharmaceutical preparation. Samples con-
taining a fixed amount of the growth hormone (50 μg 
mL
-1) and variable concentrations of excipients (lac-
tose, starch, povidon, sodium dodecylsulfate, aerosil 
and magnesium stearate) were measured. All the re-
sults obtained by using the method described above 
were compared with each other and no significant dif-
ference was observed between the amount of drugs 
found as theoretical values for t at P = 0.05 level for 
commercial formulation. 
Linearity 
For spectrofluorometry and HPLC measure-
ments, the solutions were prepared by dilution of the 
stock solution of growth hormone to reach a concen-
tration range of 1.25-5.0 μg mL
-1 (1.25, 2.5, 5, 10, 20, 
30, 40 and 50 μg mL
-1) and 10-75 μg mL
-1 (10, 20, 30, 
40, 50 and 75 μg mL
-1), respectively. Calibration cur-
ves were constructed for growth hormone standard by 
plotting the concentration of growth hormone versus 
spectrum emission and peak area response. The cali-
bration curve constructed was evaluated by its corre-
lation coefficient. The correlation coefficient (r) of all 
the calibration curves were consistently greater than 
0.99.The regression equations were calculated from 
the calibration graphs, along with the standard de-
viations of the slope and intercept on the ordinate. 
The results are shown in Table 1. Calibration curves 
 
Figure 1. The excitation and emission spectrum of growth hormone. B. YILMAZ et al.: DETERMINATION OF HUMAN GROWTH HORMONE…  CI&CEQ 18 (3) 399−405 (2012) 
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were as good as to that reported in the other papers 
[6,10]. 
Table 1. Results of regression analysis of growth hormone by 
the proposed methods 
Parameter Spectrofluorometry  HPLC 
Linearity, µg mL
-1 1.25-50  10-75 
Regression 
equation
a 
y = 0.7235x - 0.0891  y = 4862.6x + 151561
Standard devia-
tion of slope 
0.0151 1033.6 
Standard devia-
tion of intercept 
0.144 12667.5 
Correlation 
coefficient 
0.9976 0.9924 
Standard devia-
tion of correlation 
coefficient 
3.28×10
-3 2.97×10
-3 
Limit of detection 
µg mL
-1 
0.025 2.5 
Limit of quantita-
tion, µg mL
-1 
0.075 7.5 
aBased on three calibration curves; y = emission intensity (spectrofluoro-
metry method) and peak area (HPLC method); x = concentration (µg mL
-1) 
Precision and accuracy 
The precision of the spectrofluorometry and HPLC 
methods was determined by repeatability (intra-day) 
and intermediate precision (inter-day). Repeatability 
was evaluated by analyzing quality control samples 
six times per day, at three different concentrations 
which were quality control samples. The intermediate 
precision was evaluated by analyzing the same 
samples once daily for two days. The RSD of the pre-
dicted concentrations from the regression equation 
was taken as precision. The accuracy of this analytic 
method was assessed as the percentage relative 
error. For all the concentrations studied, intra- and in-
ter-day relative standard deviation values were ≤8.46% 
and for all concentrations of growth hormone the re-
lative errors were ≤6.80%. These results were given 
in Table 2. 
Limits of detection (LOD) and quantitation (LOQ) 
For spectrofluorometry measurements, LOD and 
LOQ of growth hormone were determined using cali-
bration standards. The LOD and LOQ values were 
calculated as 3.3 σ/S and 10 σ/S, respectively, where 
S is the slope of the calibration curve and σ is the 
standard deviation of y-intercept of regression equa-
tion (n = 6).  
For HPLC measurements, the LOD and LOQ of 
growth hormone were determined by injecting prog-
ressively low concentration of the standard solution 
under the chromatographic conditions. The lowest 
concentrations assayed where the signal/noise ratio 
was at least 10:1, this concentration was regarded as 
LOQ. The LOD was defined as a signal/noise ratio of 
3:1. The LOD and LOQ for spectrofluorometry were 
0.025 and 0.075 µg mL
-1, for HPLC 2.5 and 7.5 µg mL
-1, 
respectively. Among the two methods, spectrofluoro-
metry was more sensitive than HPLC (Table 1). 
Recovery 
Recovery is expressed as the amount/weight of 
the compound of interest analyzed as a percentage to 
the theoretical amount present in the medium [19]. To 
determine the recovery of spectrofluorometry and 
HPLC methods and to study the interference of for-
mulation additives, the recoveries were checked as 
   
Figure 2. HPLC chromatogram of growth hormone. B. YILMAZ et al.: DETERMINATION OF HUMAN GROWTH HORMONE…  CI&CEQ 18 (3) 399−405 (2012) 
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three different concentration levels (low, medium, high). 
Analytical recovery experiments were performed by 
adding known amount of pure drugs to pre-analyzed 
samples of commercial dosage form. 10 μg mL
-1 Hu-
matrope injectable solutions containing growth hor-
mone were prepared. For spectrofluorometry measu-
rements 1.5, 7.5 and 45 μg mL
-1 and for HPLC 
measurements 25, 45 and 65 μg mL
-1 standard solu-
tions were added into 10 μg mL
-1 Humatrope injec-
table solutions. Measurements were done and the re-
covery values were calculated by comparing concen-
tration obtained from the spiked samples with actual 
added concentrations. These values are also listed in 
Table 3. 
Table 3.  Recovery values of growth hormone in commercial 
pharmaceutical preparation (humatrope: 10 μg mL
-1) 
Method 
Added Found±SD
a   Recovery RSD
b
μg mL
-1 % 
Spectrofluorometry 1.5  1.55±0.054  103.3  3.46 
7.5 7.67±0.239 102.3 3.12 
45 45.63±1.273 101.4  2.79 
HPLC 25  24.65±0.784  98.6  3.18 
45 45.81±1.264 101.8  2.76 
65 66.49±1.309 102.3  1.97 
aStandard deviation of six replicate determinations; 
brelative standard de-
viation 
The validity of the proposed HPLC method was 
presented by recovery studies using the standard 
addition method. For this purpose, a known amount of 
reference drug was spiked to formulated injectable 
preparations and the nominal value of drug was es-
timated by the proposed method. Each level was re-
peated six times. The results were reproducible with 
low SD and RSD. No interference from the common 
excipients was observed. The RSD for intra- and in-
ter-day variation was less than 3.46% for HPLC me-
thod, which fall well below the acceptance criteria 
described by Chang et al. [6]. 
Stability 
For the determination of the stability of growth 
hormone at room temperature, 4 and -20 °C refrige-
ration temperature, low and high growth hormone 
concentrations (2 and 20 μg mL
-1 for spectrofluoro-
metry and 15 and 60 μg mL
-1 for HPLC) were kept for 
6 h and 2 days. Then, the stability measurements 
were carried out. Growth hormone samples were found 
to be stable after 6 and 24 h with no significant change 
in concentration when stored at room temperature 
and 4 °C. But, stability studies indicated that the 
samples were not stable when kept at room tempe-
rature, 4 and -20 °C refrigeration temperature after 24 
h. The results of these stability studies are given in 
Table 4. 
Ruggedness 
In this study, spectrofluorometry and HPLC de-
termination of growth hormone were carried out by a 
different analyst in same instrument with the same 
standard (Table 5). The results showed no statistical 
differences between different operators suggesting 
that the developed methods were rugged. 
System suitability 
A system suitability test of the chromatography 
system was performed before each validation run. 
Five replicate injections of a system suitability/cali-
bration standard and one injection of a check stan-
dard were made. Area relative standard deviation, 
tailing factor, and efficiency for the five suitability in-
jections were determined. The check standard was 
quantified against the average of the five suitability 
injections. For all sample analyses, the tailing factor 
was  ≤2.0, efficiency ≥1500 and RSD  ≤2.0%. The 
RSD of peak area and retention time (tR) for growth 
Table 2. Precision and accuracy of growth hormone by the proposed methods 
Added, µg mL
-1 
Intra-day Inter-day 
Found±SD
a, µg mL
-1 Precision  (RSD
b / %) Accuracy
c Found±SD
a, µg mL
-1 Precision (RSD / %)  Accuracy 
Spectrofluorometry  
2  1.91 ± 0.055  2.88  -4.50  2.06 ± 0.174  8.46  3.00 
12.5  12.21 ± 0.548  4.49  -2.32  13.35 ± 0.857  6.42  6.80 
35  34.30 ± 0.895  2.61  -2.00  36.92 ± 2.13  5.76  5.49 
HPLC 
15  14.56 ± 0.333  2.29  -2.93  14.72 ± 0.880  5.98  -1.87 
35  34.48 ± 0.548  1.59  -1.49  34.53 ± 1.471  4.26  -1.34 
60  59.41 ± 1.052  1.75  -0.98  61.39 ± 2.204  3.59  2.32 
aStandard deviation of six replicate determinations; 
brelative standard deviation; 
crelative error in %: 100(found-added)/added B. YILMAZ et al.: DETERMINATION OF HUMAN GROWTH HORMONE…  CI&CEQ 18 (3) 399−405 (2012) 
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hormone are within 2% indicating the suitability of the 
system.  
Comparison of the methods 
Spectrofluorometry and HPLC methods were 
applied for the determination of growth hormone in 
commercial Humatrope injectable form containing 
growth hormone. The results show the high reliability 
and reproducibility of two methods. A one-way anal-
ysis of variance (ANOVA) test [20,21] was performed 
based on the values observed for each pure drug 
concentration during the replicate measurement of 
the standard solutions. The results were statistically 
compared using the t-test. At 95% confidence level, 
the calculated t-values do not exceed the theoretical 
values (Table 6). 
Table 6. Application of the proposed methods in pharmaceutical 
preparation (humatrope injectable form containing 1.33 mg growth 
hormone); n: number of determination, SD:
 standard deviation, 
RSD: relative standard deviation, tc: calculated t-value, tt: tabu-
lated t-value, Ho hypothesis: no statistically significant diffe-
rence exists between two methods, tt > tc; Ho hypothesis is ac-
cepted (P > 0.05) 
Method  n 
Found±SD 
µg mL
-1 
RSD 
% 
Recovery
% 
t-Test 
Spectrofluorometry 10  1.344±0.071  5.28  101.1  tt: 1.78 
HPLC 10  1.342±0.043  3.20  100.9  tc: 1.26 
Therefore, there is no significant difference be-
tween spectrofluorometry and HPLC methods. Also, 
this is suggested that the two methods are equally 
applicable. 
CONCLUSIONS 
The proposed methods were found to be accu-
rate, precise and easy for the determination of growth 
hormone. The HPLC method is found to be superior 
to earlier reported methods, as the mobile phase is 
simple to prepare and economical. The medium for 
dissolving of growth hormone is the same at HPLC 
and spectrofluorometry analysis. The sample reco-
veries in a formulation were in good agreement with 
their respective label claims. No extraction procedure 
is involved. 
These methods can be used effectively, without 
separation and interference, for routine analysis of 
growth hormone in pure form and its formulations and 
can also be used for dissolution or similar studies. On 
the other hand, spectrofluorometry method is also 
suitable for analysis of sample during accelerated 
stability studies, routine analysis of formulations and 
raw materials. 
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Table 4. Stability of growth hormone in solution (n=6) 
Concentration, μg mL
-1 
Intra-day Inter-day 
Room temperature 
6 h 
Room temperature
24h 
Refrigerator (4 °C)
24 h 
Refrigerator (4 °C) 
48 h 
Frozen (-20 °C) 
48 h 
Spectrofluorometry  
2 2.13±6.29  2.23±9.12  2.08±3.56  2.26±7.49  2.20±8.26 
20 21.0±4.19  22.3±9.16  2.06±4.64  22.4±6.16  21.8±6.56 
HPLC 
15 14.7±4.63  16.9±9.28  14.5±4.34  14.3±5.65  14.3±4.28 
60 57.6±3.32  66.6±8.26  58.8±3.46  55.8±4.57  57.6±3.76 
Table 5. The results of analyses of standard growth hormone by different analyst (average of six replicate determinations) 
Method  Added, µg mL
-1 
Intra-day Inter-day 
Found±SD
a, µg mL
-1 Recovery, % RSD
b / %  Found±SD
a, µg mL
-1 Recovery,  % RSD
b / %
Spectrofluorometry  5 4.77±0.201  95.4  4.21  4.87±0.139  97.4  2.84 
15 14.40±0.517  96.0  3.59  14.29±0.392  95.3  2.74 
35 33.85±0.941  96.7  2.78  33.35±0.804  95.3  2.41 
HPLC  15 15.17±0.419  101.1  2.76  15.43±0.446  102.9  2.89 
25 24.18±0.455  96.7  1.88  25.42±0.803  101.7  3.16 
50 49.14±0.968  98.3  1.97  50.73±1.494  101.4  2.94 
             B. YILMAZ et al.: DETERMINATION OF HUMAN GROWTH HORMONE…  CI&CEQ 18 (3) 399−405 (2012) 
 
 405
REFERENCES 
[1]  Y.H. Cheng, A.M. Dyer, I. Jabbal-Gill, M. Hinchcliffe, R. 
Nankervis, A. Smith, P. Watts, Eur. J. Pharm. 26 (2005) 
9-15 
[2]  M. Ikehara, E. Ohtsuka, T. Tokunaga, Y. Taniyame, S. 
Iwai, K. Kitano, S. Miyamoto, T. Ohgi, Y. Sakuragawa, K. 
Fujiyama, T. Ikari, M. Kobayashi, T. Miyake, S. Shiba-
hara, A. Ono, T. Ueda, T. Tanaka, H. Baba, T. Miki, A. 
Sakurai, T. Oishi, O. Chisaka, K. Matsubara, Proc. Natl. 
Acad. Sci. USA 81 (1984) 5956-5960 
[3]  C.N. Chang, M. Key, B. Bochner, H. Heyneker, G. Gray. 
Gene 55 (1987) 189-196 
[4]  G.W. Becker, H.M. Hsiung. FEBS Lett. 204 (1986) 145- 
–150 
[5]  T.M. McNerney, S.K. Watson, J.H. Sim, R.L. Briden-
baugh, J. Chromatogr. 744 (1996) 223-229 
[6]  J.P. Chang T.H. Ferguson, P.A. Record, D.A. Dickson, 
D.E. Kiehl, A.S. Kennington, J. Chromatogr., A 736 
(1996) 97-104 
[7]  P. Gellerfors, G. Eketorp, K. Fhölenhag, B. Pavlu, S. 
Johansson, L. Fryklund. J. Pharm. Biomed. Anal. 7 
(1989) 173-183 
[8]  S. Wu, W.S. Hancock, B. Pavlu, P. Gellerfors. J. Chroma-
togr. 500 (1990) 595-606 
[9]  R.M. Riggin, G.K. Dorulla, D.J. Miner. Anal. Biochem. 167 
(1987) 199-209 
[10]  [10] A. Oliva, M. Llabrés, J.B. Farina, J. Pharm. Biomed. 
Anal. 25 (2001) 833-841. 
[11]  F. Hepner, E. Cszasar, E. Roitinger, G. Lubec, Proteome 
Science 3 (2005) 1-12 
[12]  S.A. Charman, A.M. Segrave, G.A. Edwards, C.J.H. Por-
ter, J. Pharm. 89 (2000) 168-177 
[13]  C. Vermehren, H.S. Hansen, M.K. Thomsen, Int. J. 
Pharm. 128 (1996) 239-250 
[14]  N. Vahl, S.B. Jensen, M.H. Rasmussen, S. Susgaard, 
J.O.L. Jorgensen, J.S. Christiansen, U.F. Rasmussen, J. 
Hilsted, Pharmacol-Toxicol. 79 (1996) 144-149 
[15]  M. Katakam, W.R. Ravis, D.L. Golden, A.K. Banga, Int. J. 
Pharm. 152 (1997) 53-58 
[16]  N. Mzoughi, M. Dachraoui, J.P. Villeneuve, C.R. Chimie 8 
(2005) 97-102 
[17]  B. Yilmaz, A. Asci, S.S. Palabiyik, J. of Chromatogr. Sci. 
49 (2011) 422-427 
[18]  International Conference on Harmonisation (ICH) of 
Technical requirements for Registration of Pharmaceu-
ticals for Human Use: Harmonised Tripartite Guideline on 
Validation of Analytical Procedures: Methodology, Re-
commended for Adoption at Step 4 of the ICH Process on 
November (1996) by the ICH Steering Committee, Pub-
lished by IFPMA, Switzerland 
[19]  Center for Drug Evaluation and Research (CDER) Re-
viewer Guidance Validation of  Chromatographic Me-
thods, 1994 
[20]  R. Duncan, R.G. Knapp, M.C. Miller, Introductory Biosta-
tistics for the Health Sciences, 2nd Edition, Delmer Pub-
lishers, 1983, pp. 115-150 
[21]  S. Bolton, Pharmaceutical Statistics: Practical and Clini-
cal Application, 3
rd ed., Marcel Dekker, New York, 1997, 
pp. 216-269. 
 
 
 
 
BILAL YILMAZ
1 
YUCEL KADIOGLU
1 
KADEM MERAL
2 
YAVUZ ONGANER
2 
1Department of Analytical Chemistry, 
Faculty of Pharmacy, Ataturk 
University, Erzurum, Turkey 
2Department of Chemistry, Faculty of 
Science, Ataturk University, Erzurum, 
Turkey 
NAUČNI RAD 
   SPEKTROFLUOROMETRIJSKO I HPLC 
ODREĐIVANJE HUMANOG HORMONA RASTA 
U ČISTOJ SUPSTANCI I FARMACEUTSKOJ 
FORMULACIJI 
U ovom radu su razvijene dve metode: spektrofluorometrijska i HPLC metoda za odre-
đivanje humanog hormona rasta u čistoj supstanci i farmaceutskoj formulaciji. Za obe 
predložene metode izabrani su optimalni rastvarači i nađene talasne dužine određivanja 
sa maksimalnom osetljivošću. Takođe, za HPLC metodu su optimizovani hromatografski 
uslovi određivanja. Nađeno je da spektrofluoromtrijska metoda ima zadovoljavajuću line-
arnost u opsegu koncentracija 1,25-50 μg mL
-1 , a HPLC metoda u opsegu koncentracija 
10-75 μg mL
-1. Varijabilnost metode u toku jednog i više dana za spektrofluoromtrijsku 
metodu je < 8,46%, a za HPLC metodu < 5,98%. Određeni su limiti kvantifikacije za obe 
metode i oni iznose: 0,075 μg mL
-1 za spektrofluoromtrijsku metodu i 7,5 μg mL
-1 za 
HPLC metodu. Odabrani uslovi određivanja omogućavaju određivanje bez interferencija 
pomoćnih supstanci iz tableta. Metode su primenjene za kontrolu humanog hormona 
rasta u komercijalnim dozirnim oblicima, za određivanje sadržaja hormona i proveru jed-
nobraznosti sadržaja formulacije. 
Ključne reči: hormon rasta; spektrofluorometrija; HPLC; validacija. 
 
 